(NASDAQ: SCPH) Scpharmaceuticals's forecast annual revenue growth rate of 124.61% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Scpharmaceuticals's revenue in 2023 is $7,497,000.On average, 3 Wall Street analysts forecast SCPH's revenue for 2023 to be $457,651,663, with the lowest SCPH revenue forecast at $422,651,818, and the highest SCPH revenue forecast at $476,944,610. On average, 3 Wall Street analysts forecast SCPH's revenue for 2024 to be $1,365,244,981, with the lowest SCPH revenue forecast at $1,183,898,448, and the highest SCPH revenue forecast at $1,513,312,973.
In 2025, SCPH is forecast to generate $3,201,374,149 in revenue, with the lowest revenue forecast at $2,360,696,518 and the highest revenue forecast at $3,751,007,986.